Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update
Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors
SITC presentation from ongoing ADXS-503 Phase 1/2 clinical trial demonstrated disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA®
Continued durable tumor control with two patients on treatment beyond 12 months
Strengthened balance sheet through
Fiscal Year 2020 and Recent Key Accomplishments:
- Presented updated clinical data from the ongoing Phase 1/2 trial of ADXS-503 as a monotherapy and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in non-small cell lung cancer (NSCLC) at the 2020
Society for Immunotherapy of Cancer (SITC) Annual Meeting- In the Part B combination arm, reported disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA®
- Reported durable and sustained tumor control, with confirmed stable disease and a partial response lasting out to 10 months
- Biomarker data across 9 patients across trial arms confirmed on-mechanism activation of innate and adaptive immune responses to ADXS-503 with activation of cytotoxic -and/or memory CD8+ T cells as well as 100% efficient priming by ADXS-503
- Across trial arms, ADXS-503 appeared safe and well tolerated as a monotherapy and in combination with KEYTRUDA® with no added toxicities from combination therapy
- Initiated ADXS-503 Part B combination arm efficacy expansion which will enroll up to 15 patients to evaluate the potential of ADXS-503 in combination with KEYTRUDA® to restore and/or enhance responsiveness to checkpoint inhibitors in PD-1/L-1 refractory NSCLC patients
- Initiated ADXS-503 Part C combination arm to evaluate ADXS-503 in combination with KEYTRUDA® as a first line treatment in patients with metastatic NSCLC that would receive KEYTRUDA® alone as per label indication with PD-L1 expression ≥ 1% or who are unfit to receive the standard of care regimen of KEYTRUDA® in combination with platinum based-chemotherapy
- Announced FDA Clearance of new Investigational New Drug (IND) application for ADXS-504 for the treatment of prostate cancer at a leading medical institution
- Announced common stock purchase agreement for up to
$20 million of common stock withLincoln Park Capital - Announced an at-the-market offering program for up to
$40 million of common stock with A.G.P./Alliance Global Partners , as sales agent - Announced closing of
$9.2 million public offering of common stock and warrants, with proceeds being used to fund continued development and expansion of our product pipeline, including investment in our ADXS-HOT program and for general corporate purposes - Cash runway currently anticipated to take the Company into fiscal second quarter of 2022
Management Commentary
“Fiscal year 2020 was transformative for
Balance Sheet Highlights
As of October 31, 2020, Advaxis had cash and cash equivalents of $25.2 million. The Company used $21.9 million in cash to fund operations during fiscal year 2020, mainly attributed to funding research and development and general and administrative activities. Throughout fiscal year 2020, the Company continued to prioritize its strategic pipeline across all programs and reduced its annual operating expenses by approximately $12.2 million, or nearly 31%.
Fiscal Year 2020 Financial Information
Research and development expenses for fiscal year 2020 were $15.6 million, compared with $26.7 million for fiscal year 2019. The $11.1 million decrease was primarily attributable to decreases in clinical trial costs, laboratory costs, drug manufacturing process validation and drug stability studies.
General and administrative expenses for fiscal year 2020 were $11.1 million, compared to $12.2 million for fiscal year 2019.
The net loss for the fiscal year ended October 31, 2020 was $26.5 million or $0.43 per share based on about 61 million weighted average shares outstanding. This compares with a net loss for fiscal year 2019 of $16.6 million or $1.09 per share based on 15.2 million weighted average shares outstanding.
About
To learn more about
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statements that express the current beliefs and expectations of management, including but not limited to statements related to the expected clinical development of the Company’s drug product candidates, statements about the Company’s balance sheet position, and statements related to the goals, plans and expectations for the Company’s ongoing clinical studies. These and other risks are discussed in the Company’s filings with the
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,
Contact:
Tim McCarthy, LifeSci Advisors, LLC
212.915.2564
tim@lifesciadvisors.com
BALANCE SHEETS
(In thousands, except share and per share data)
| 2020 | 2019 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 25,178 | $ | 32,363 | ||||
| Deferred expenses | 1,808 | 2,353 | ||||||
| Prepaid expenses and other current assets | 865 | 1,433 | ||||||
| Total current assets | 27,851 | 36,149 | ||||||
| Property and equipment (net of accumulated depreciation) | 2,393 | 4,350 | ||||||
| Intangible assets (net of accumulated amortization) | 3,261 | 4,575 | ||||||
| Operating right-of-use asset (net of accumulated amortization) | 4,839 | - | ||||||
| Other assets | 182 | 183 | ||||||
| Total assets | $ | 38,526 | $ | 45,257 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 410 | $ | 976 | ||||
| Accrued expenses | 1,737 | 3,478 | ||||||
| Current portion of operating lease liability | 962 | - | ||||||
| Deferred revenue | 165 | - | ||||||
| Common stock warrant liability | 17 | 19 | ||||||
| Other current liabilities | - | 48 | ||||||
| Total current liabilities | 3,291 | 4,521 | ||||||
| Operating lease liability, net of current portion | 5,055 | - | ||||||
| Other liabilities | - | 1,205 | ||||||
| Total liabilities | 8,346 | 5,726 | ||||||
| Commitments and contingencies – Note 9 | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, Preferred Stock; 0 shares issued and outstanding at 2019. Liquidation preference of |
- | - | ||||||
| Common stock - 78,074,023 and 50,201,671 shares issued and outstanding at 2020 and 2019. |
78 | 50 | ||||||
| Additional paid-in capital | 440,840 | 423,750 | ||||||
| Accumulated deficit | (410,738 | ) | (384,269 | ) | ||||
| Total stockholders’ equity | 30,180 | 39,531 | ||||||
| Total liabilities and stockholders’ equity | $ | 38,526 | $ | 45,257 | ||||
STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
| Year Ended |
||||||||
| 2020 | 2019 | |||||||
| Revenue | $ | 253 | $ | 20,884 | ||||
| Operating expenses: | ||||||||
| Research and development expenses | 15,612 | 26,677 | ||||||
| General and administrative expenses | 11,090 | 12,179 | ||||||
| Total operating expenses | 26,702 | 38,856 | ||||||
| Loss from operations | (26,449 | ) | (17,972 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 110 | 435 | ||||||
| Net changes in fair value of derivative liabilities | - | 2,589 | ||||||
| Loss on shares issued in settlement of warrants | (77 | ) | (1,607 | ) | ||||
| Other expense | (3 | ) | (7 | ) | ||||
| Net loss before income tax benefit | (26,419 | ) | (16,562 | ) | ||||
| Income tax expense | 50 | 50 | ||||||
| Net loss | $ | (26,469 | ) | $ | (16,612 | ) | ||
| Net loss per common share, basic and diluted | $ | (0.43 | ) | $ | (1.09 | ) | ||
| Weighted average number of common shares outstanding, basic, and diluted | 61,003,839 | 15,207,637 | ||||||
Source: Advaxis, Inc.